

纳/米/科/学/技/术/大系

(影印版)

Therapeutic Micro/Nano Technology

# 面向医学治疗的 微纳米技术

〔加〕 Tejal Desai

〔美〕 Sangeeta Bhatia



科学出版社  
[www.sciencep.com](http://www.sciencep.com)

NANOSCIENCE AND NANOTECHNOLOGY

纳米科学技术大系

Therapeutic Micro/Nano Technology

面向医学治疗的微纳米技术

〔加〕 Tejal Desai

〔美〕 Sangeeta Bhatia

科学出版社

北京

图字:01-2008-2607

## 内 容 简 介

本书讨论了正在兴起的治疗性微米和纳米技术领域。本书所覆盖的主题包括:基于细胞的治疗技术,再生医学——细胞与微米和纳米系统整合(融合),MEMS与细胞和组织的集成;药物的传递-用于血管内药物靶向传递的纳米粒子和非血管系统的药物传递系统(植入性的、口服的、吸入性的);用于生物界面的分子表面工程,生物分子图案化和细胞图案化。

本书可供从事纳米科技、材料科学、生物化学和医学的科研人员,高等院校研究生、教学人员参考。

Ferrari, Mauro (Editor-in-chief); BioMEMS and Biomedical Nanotechnology  
Desai, Tejal; Bhatia, Sangeeta (Eds.); BioMEMS and Biomedical Nanotechnology Volume III; Therapeutic Micro/Nano Technology

© 2006 Springer Science+Business Media, LLC

This reprint has been authorized by Springer-Verlag (Berlin/Heidelberg/New York) for sale in the People's Republic of China only and not for export therefrom.

本书英文影印版由 Springer 出版公司(柏林/海德堡/纽约)授权,仅限在中华人民共和国和销售。不得出口。

### 图书在版编目(CIP)数据

面向医学治疗的微纳米技术:英文/(加)德塞(Desai, T.), (美)巴蒂亚(Bhatia, S.)编著. Therapeutic Micro/Nano Technology. —影印本. —北京:科学出版社, 2008

(纳米科学技术大系)

ISBN 978-7-03-022339-5

I. 面… II. ①德…②巴… III. 纳米材料-应用-医学-英文 IV. R  
中国版本图书馆 CIP 数据核字(2008)第 090772 号

责任编辑:杨 震/责任印制:钱玉芬/封面设计:王 浩

科学出版社出版

北京东黄城根北街 16 号

邮政编码: 100717

<http://www.sciencep.com>

双青印刷厂印刷

科学出版社发行 各地新华书店经销

\*

2008 年 5 月第 一 版 开本:B5(720×1000)

2008 年 5 月第一次印刷 印张:24 3/4

印数:1—2 000 字数:470 000

定价:88.00 元

(如有印装质量问题,我社负责调换〈双青〉)

## Dedicated to Richard Smalley (1943–2005), in Memoriam



To Rick,

father founder of nanotechnology  
prime inspiration for its applications to medicine  
gracious mentor to its researchers  
our light—forever in the trenches with us

(Rick Smalley received the 1996 Chemistry Nobel Prize  
for the co-discovery of carbon-60 buckyballs)

# List of Contributors

## VOLUME III

**Dirk R. Albrecht**, Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts USA

**Ravi V. Bellamkonda**, WHC Dept. of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, Georgia USA

**Edward C. Benzel**, Department of Neurosurgery, The Cleveland Clinic Foundation, Cleveland, Ohio USA

**Kiran Bhadriraju**, Dept. of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland USA

**Sangeeta N. Bhatia**, Harvard—MIT Division of Health Sciences & Technology, Electrical Engineering & Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts USA

**Tony Bolarski**, IMEDD Inc., Columbus, Ohio USA

**Anthony Bolarski**, IMEDD Inc., Columbus, Ohio USA

**Warren C.W. Chan**, Institute of Biomaterials and Biomedical Engineering, Toronto, Canada

**Alice A. Chen**, Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts USA

**Christopher S. Chen**, Dept. of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland USA

**Michael Cohen**, IMEDD Inc., Columbus, Ohio USA

**Carlo Cosentino**, Dept. of Experimental & Clinical Medicine, University of Catanzaro, Catanzaro, Italy

**Frédérique Cunin**, UMR CNRS/ENSCM, Montpellier cedex, France

**Tejal A. Desai**, Dept. of Bioengineering, and Physiology, University of California, San Francisco, California USA

**Rebekah A. Drezek**, Dept. of Bioengineering, Rice University, Houston, Texas USA

**Lisa A. Ferrara**, Spine Research Laboratory, The Cleveland Clinic Foundation, Cleveland, Ohio USA

**Mauro Ferrari, Ph.D.**, Professor, Brown Institute of Molecular Medicine Chairman, Department of Biomedical Engineering, University of Texas Health Science Center, Houston, TX; Professor of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX; Professor of Bioengineering, Rice University, Houston, TX; Professor of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX; President, the Texas Alliance for NanoHealth, Houston, TX

**Hans Fischer**, Department of Materials Science & Engineering, Institute of Biomaterials and Biomedical Engineering, Toronto, Canada

**Aaron J. Fleischman**, Dept. of Biomedical Engineering, The Cleveland Clinic Foundation, Cleveland, Ohio USA

**Albert Folch**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Nobuyuki Futai**, Dept. of Biomedical Engineering & Macromolecular Science & Engineering, University of Michigan, Ann Arbor, Michigan USA

**Darren S. Gray**, Dept. of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland USA

**Jay T. Groves**, Dept. of Chemistry, University of California, Berkeley, Berkeley, California USA

**Naomi J. Halas**, Dept. of Bioengineering, Rice University, Houston, Texas USA

**Leon R. Hirsch**, Dept. of Bioengineering, Rice University, Houston, Texas USA

**Allan S. Hoffman**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Dongeun Huh**, Dept. of Biomedical Engineering & Macromolecular Science & Engineering, University of Michigan, Ann Arbor, Michigan USA

**Laura J. Itle**, Dept. of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania USA

**Anjana Jain**, WHC Dept. of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, Georgia USA

**Wen Jiang**, Institute of Biomaterials and Biomedical Engineering, Toronto, Canada

**Yoko Kamotani**, Dept. of Biomedical Engineering & Macromolecular Science & Engineering, University of Michigan, Ann Arbor, Michigan USA

**Won-Gun Koh**, Dept. of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania USA

**Samarth Kulkarni**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Yang Yang Li**, Dept. of Chemistry & Biochemistry, The University of California, San Diego, La Jolla, California USA

**Wendy F. Liu**, Dept. of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland USA

**Noah Malmstadt**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Sawitri Mardiyani**, Institute of Biomaterials and Biomedical Engineering, Toronto, Canada

**Kristie Melnik**, IMEDD Inc., Columbus, Ohio USA

**Samir Mitragotri**, Dept. of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, California USA

**Michael V. Pishko**, Dept. of Chemical Engineering & Materials Science, The Pennsylvania State University, University Park, Pennsylvania USA

**Amy Pope-Harmon**, Dept. of Internal Medicine, The Ohio State University, Columbus, Ohio USA

**Arfaan Rampersaud**, IMEDD Inc., Columbus, Ohio USA

**Shuvo Roy**, Dept. of Biomedical Engineering, The Cleveland Clinic Foundation, Cleveland, Ohio USA

**Erkki Ruoslahti**, The Burnham Institute, Cancer Research Center, La Jolla, California USA

**Michael J. Sailor**, Dept. of Chemistry & Biochemistry, The University of California, San Diego, La Jolla, California USA

**John Shapiro**, Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL

**Sadhana Sharma**, Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL

**Anupam Singhal**, Institute of Biomaterials and Biomedical Engineering, Toronto, Canada

**Piyush M. Sinha**,

**Patrick S. Stayton**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Shuichi Takayama**, Dept. of Biomedical Engineering & Macromolecular Science & Engineering, University of Michigan, Ann Arbor, Michigan USA

**Sarah L. Tao**, Dept. of Biomedical Engineering, Boston University, Boston, Massachusetts USA

**Anna Tourovskaia**, Dept. of Bioengineering, University of Washington, Seattle, Washington USA

**Valerie Liu Tsang**, Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts USA

**Robbie J. Walczak**, IMEDD Inc., Foster City, CA

**Jennifer L. West**, Dept. of Bioengineering, Rice University, Houston, Texas USA

**Teri West**, IMEDD Inc., Foster City, CA

**Shuguang Zhang**, Center for Bits and Atoms, Massachusetts Institute of Technology, Cambridge, Massachusetts USA

**Xiaojun Zhao**, Center for Biomedical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts USA



# Foreword

Less than twenty years ago photolithography and medicine were total strangers to one another. They had not yet met, and not even looking each other up in the classifieds. And then, nucleic acid chips, microfluidics and microarrays entered the scene, and rapidly these strangers became indispensable partners in biomedicine.

As recently as ten years ago the notion of applying nanotechnology to the fight against disease was dominantly the province of the fiction writers. Thoughts of nanoparticle-vehicled delivery of therapeutics to diseased sites were an exercise in scientific solitude, and grounds for questioning one's ability to think "like an established scientist". And today we have nanoparticulate paclitaxel as the prime option against metastatic breast cancer, proteomic profiling diagnostic tools based on target surface nanotexturing, nanoparticle contrast agents for all radiological modalities, nanotechnologies embedded in high-distribution laboratory equipment, and no less than 152 novel nanomedical entities in the regulatory pipeline in the US alone.

This is a transforming impact, by any measure, with clear evidence of further acceleration, supported by very vigorous investments by the public and private sectors throughout the world. Even joining the dots in a most conservative, linear fashion, it is easy to envision scenarios of personalized medicine such as the following:

- patient-specific prevention supplanting gross, faceless intervention strategies;
- early detection protocols identifying signs of developing disease at the time when the disease is most easily subdued;
- personally tailored intervention strategies that are so routinely and inexpensively realized, that access to them can be secured by everyone;
- technologies allowing for long lives in the company of disease, as good neighbors, without impairment of the quality of life itself.

These visions will become reality. The contributions from the worlds of small-scale technologies are required to realize them. Invaluable progress towards them was recorded by the very scientists that have joined forces to accomplish the effort presented in this 4-volume collection. It has been a great privilege for me to be at their service, and at the service of the readership, in aiding with its assembly. May I take this opportunity to express my gratitude to all of the contributing Chapter Authors, for their inspired and thorough work. For many of them, writing about the history of their specialty fields of *BioMEMS* and *Biomedical Nanotechnology* has really been reporting about their personal, individual adventures through scientific discovery and innovation—a sort

of family album, with equations, diagrams, bibliographies and charts replacing Holiday pictures....

It has been a particular privilege to work with our Volume Editors: Sangeeta Bhatia, Rashid Bashir, Tejal Desai, Michael Heller, Abraham Lee, Jim Lee, Mihri Ozkan, and Steve Werely. They have been nothing short of outstanding in their dedication, scientific vision, and generosity. My gratitude goes to our Publisher, and in particular to Greg Franklin for his constant support and leadership, and to Angela De Pina for her assistance.

Most importantly, I wish to express my public gratitude in these pages to Paola, for her leadership, professional assistance throughout this effort, her support and her patience. To her, and our children Giacomo, Chiara, Kim, Ilaria and Federica, I dedicate my contribution to BioMEMS and Biomedical Nanotechnology.

With my very best wishes

Mauro Ferrari, Ph.D.

*Professor, Brown Institute of Molecular Medicine Chairman  
Department of Biomedical Engineering  
University of Texas Health Science Center, Houston, TX*

*Professor of Experimental Therapeutics  
University of Texas M.D. Anderson Cancer Center, Houston, TX*

*Professor of Bioengineering  
Rice University, Houston, TX*

*Professor of Biochemistry and Molecular Biology  
University of Texas Medical Branch, Galveston, TX*

*President, the Texas Alliance for NanoHealth  
Houston, TX*

# Preface

The human body is composed of structures organized in a hierarchical fashion: from biomolecules assembled into polymers, to multimeric assemblies such as cellular organelles, to individual cells, to tissues, to organ systems working together in health and disease- each dominated by a characteristic length scale. Decades of science and engineering are now converging to provide tools that enable the orderly manipulation of biological systems at previously inaccessible, though critically important, length scales ( $<100$  microns). Thus, the approaches described in this volume provide a snapshot of how micro- and nanotechnologies can enable the investigation, prevention, and treatment of human disease.

The volume is divided into three parts. The first part, *Cell-based therapeutics*; covers the merger of cells with micro- and nanosystems for applications in regenerative medicine spanning the development of novel nanobiomaterials, methods of tissue assembly with control over tissue microarchitecture, and methods to specify patterns of protein distribution that vary on the micro- and nanoscale for application in tissue regeneration (A), and therapeutic applications of integrating MEMS with cells and tissues including label-free microfluidic sorting of cells based on their function, using living cell arrays as biosensors, and micron-scale devices for surgical applications (B). The second part, *Drug Delivery*; covers intravascular delivery of nanoparticles such as semiconductor quantum dots and metal nanoshells in the context of vascular specialization or 'zip codes' (A) as well as non-vascular modes of delivery including implantation, oral, and inhalation using both encapsulated drugs as well as living cells that produce therapeutic products (B). Finally, the third part, *Molecular Surface Engineering for the Biological Interface*; covers platforms that provide enabling tools for fundamental investigations of cells in culture as they interact with biomolecular structures such as responsive biomaterials and lipid bilayers (A) as well as micropatterned adhesive and fluidic environments (B).

We would like to thank the contributing authors, our co-editors in this exciting compilation of volumes, and Dr. Mauro Ferrari for his tireless efforts to lead this endeavor. We hope the collected works will provide an excellent reference for an audience with a

diversity of background and interests including industry, students, academic researchers, policy-makers, and enthusiasts.

Sangeeta N. Bhatia

*Massachusetts Institute of Technology*

Tejal Desai

*University of California, San Francisco*

Mauro Ferrari

*Professor, Brown Institute of Molecular Medicine Chairman*

*Department of Biomedical Engineering*

*University of Texas Health Science Center, Houston, TX*

*Professor of Experimental Therapeutics*

*University of Texas M.D. Anderson Cancer Center, Houston, TX*

*Professor of Bioengineering, Rice University, Houston, TX*

*Professor of Biochemistry and Molecular Biology*

*University of Texas Medical Branch, Galveston, TX*

*President, the Texas Alliance for NanoHealth, Houston, TX*

# Contents

<b>List of Contributors</b> .....	xvii
<b>Foreword</b> .....	xxi
<b>Preface</b> .....	xxiii
 <b>I. Cell-based Therapeutics</b> .....	 1
<b>1. Nano- and Micro-Technology to Spatially and Temporally Control</b>	
<b>Proteins for Neural Regeneration</b> .....	3
<i>Anjana Jain and Ravi V. Bellamkonda</i>	
1.1 Introduction .....	3
1.1.1 Response after Injury in CNS and PNS .....	4
1.1.2 Nano- and Micro-scale Strategies to Promote Axonal Outgrowth in the CNS and PNS .....	4
1.2 Spatially Controlling Proteins .....	6
1.2.1 Spatial Control: Permissive Bioactive Hydrogel Scaffolds for Enhanced Regeneration .....	7
1.2.2 Spatial Control: Chemical vs. Photochemical Crosslinkers for Immobilization of Bioactive Agents .....	8
1.2.3 Other Hydrogel Scaffolds .....	10
1.2.4 Spatial Control: Contact Guidance as a Strategy to Promote Regeneration .....	10
1.2.5 Spatial Control: Nerve Guide Conduits Provide an Environment for Axonal Regeneration .....	11
1.2.6 Spatial Control: Cell-scaffold Constructs as a Way of Combining Permissive Substrates with Stimuli for Regeneration .....	12
1.3 Temporally Controlling the Release of Proteins .....	13
1.3.1 Temporal Control: Osmotic Pumps Release Protein to Encourage Axonal Outgrowth .....	14
1.3.2 Temporal Control: Slow Release of Trophic Factors Using Microspheres .....	15
1.3.3 Temporal Control: Lipid Microtubules for Sustained Release of Stimulatory Trophic Factors .....	16
1.3.4 Temporal Control: Demand Driven Release of Trophic Factors .....	17

1.4 Conclusion .....	17
References.....	18
<b>2. 3-D Fabrication Technology for Tissue Engineering .....</b>	<b>23</b>
<i>Alice A. Chen, Valerie Liu Tsang, Dirk Albrecht, and Sangeeta N. Bhatia</i>	
2.1 Introduction .....	23
2.2 Fabrication of Acellular Constructs.....	24
2.2.1 Heat-Mediated 3D Fabrication .....	24
2.2.2 Light-Mediated Fabrication .....	27
2.2.3 Adhesive-Mediated Fabrication .....	28
2.2.4 Indirect Fabrication by Molding .....	29
2.3 Fabrication of Cellular Constructs .....	30
2.4 Fabrication of Hybrid Cell/Scaffold Constructs .....	31
2.4.1 Cell-laden Hydrogel Scaffolds by Molding .....	31
2.4.2 Cell-laden Hydrogel Scaffolds by Photopatterning .....	32
2.5 Future Directions .....	34
Acknowledgements.....	36
References.....	36
<b>3. Designed Self-assembling Peptide Nanobiomaterials .....</b>	<b>39</b>
<i>Shuguang Zhang and Xiaojun Zhao</i>	
3.1 Introduction .....	40
3.2 Peptide as Biological Material Construction Units .....	40
3.2.1 Lego Peptide .....	41
3.2.2 Surfactant/detergent Peptides .....	42
3.2.3 Molecular Ink Peptides .....	45
3.3 Peptide Nanofiber Scaffold for 3-D Cell Culture, Tissue Engineering and Regenerative Medicine .....	47
3.3.1 Ideal Synthetic Biological Scaffolds .....	47
3.3.2 Peptide Scaffolds .....	48
3.3.3 PuraMatrix <i>in vitro</i> Cell Culture Examples .....	49
3.3.4 Extensive Neurite Outgrowth and Active Synapse Formation on PuraMatrix .....	50
3.3.5 Compatible with Bioproduction and Clinical Application .....	51
3.3.6 Synthetic Origin and Clinical-Grade Quality.....	51
3.3.7 Tailor-Made PuraMatrix.....	51
3.4 Peptide Surfactants/Detergents Stabilize Membrane Proteins.....	52
3.5 Perspective and Remarks.....	52
Acknowledgements.....	53
References.....	53
<b>4. At the Interface: Advanced Microfluidic Assays for Study of Cell Function .....</b>	<b>55</b>
<i>Yoko Kamotani, Dongeun Huh, Nobuyuki Futai, and Shuichi Takayama</i>	
4.1 Introduction .....	55
4.2 Microfabrication .....	56
4.2.1 Soft Lithography .....	57

4.3 Microscale Phenomena .....	58
4.3.1 Scaling Effects .....	59
4.3.2 Laminar Flow .....	59
4.3.3 Surface Tension .....	60
4.4 Examples of Advanced Microfluidic Cellular Bioassays .....	61
4.4.1 Patterning with Individual Microfluidic Channels .....	61
4.4.2 Multiple Laminar Streams .....	63
4.4.3 PARTCELL .....	66
4.4.4 Microscale Integrated Sperm Sorter (MISS) .....	68
4.4.5 Air-Sheath Flow Cytometry .....	69
4.4.6 Immunoassays .....	71
4.5 Conclusion .....	75
References .....	75
<b>5. Multi-phenotypic Cellular Arrays for Biosensing .....</b>	<b>79</b>
<i>Laura J. Itle, Won-Gun Koh, and Michael V. Pishko</i>	
5.1 Introduction .....	79
5.2 Fabrication of Multi-Phenotypic Arrays .....	81
5.2.1 Surface Patterning .....	81
5.2.2 Photolithography .....	81
5.2.3 Soft Lithography .....	82
5.2.4 Poly(ethylene) Glycol Hydrogels .....	83
5.3 Detection methods for cell based sensors .....	84
5.3.1 Microelectronics .....	84
5.3.2 Fluorescent Markers For Gene Expression and Protein Up-regulation .....	84
5.3.3 Intracellular Fluorescent Probes for Small Molecules .....	86
5.4 Current Examples of Multi-Phenotypic Arrays .....	87
5.5 Future Work .....	88
References .....	90
<b>6. MEMS and Neurosurgery .....</b>	<b>95</b>
<i>Shuvo Roy, Lisa A. Ferrara, Aaron J. Fleischman, and Edward C. Benzel</i>	
Part I: Background .....	95
6.1 What is Neurosurgery? .....	95
6.2 History of Neurosurgery .....	95
6.3 Conventional Neurosurgical Treatments .....	99
6.3.1 Hydrocephalus .....	99
6.3.2 Brain Tumors .....	101
6.3.3 Parkinson Disease .....	103
6.3.4 Degenerative Disease of the Spine .....	104
6.4 Evolution of Neurosurgery .....	106
Part II: Applications .....	107
6.5 MEMS for Neurosurgery .....	107
6.6 Obstacles to Neurosurgical Employment of MEMS .....	108
6.6.1 Biocompatibility Assessment .....	109

6.7 Opportunities .....	110
6.7.1 Intracranial Pressure Monitoring .....	110
6.7.2 Neural Prostheses .....	112
6.7.3 Drug Delivery Systems .....	113
6.7.4 Smart Surgical Instruments and Minimally Invasive Surgery .....	114
6.7.5 In Vivo Spine Biomechanics .....	116
6.7.6 Neural Regeneration .....	118
6.8 Prospects for MEMS in Neurosurgery .....	120
Acknowledgements .....	120
References .....	120
 <b>II. Drug Delivery .....</b>	<b>125</b>
 <b>7. Vascular Zip Codes and Nanoparticle Targeting .....</b>	<b>127</b>
<i>Erkki Ruoslahti</i>	
7.1 Introduction .....	127
7.2 In vivo Phage Display in Vascular Analysis .....	128
7.3 Tissue-Specific Zip Codes in Blood Vessels .....	128
7.4 Special Features of Vessels in Disease .....	129
7.5 Delivery of Diagnostic and Therapeutic Agents to Vascular Targets .....	131
7.6 Homing Peptides for Subcellular Targeting .....	131
7.7 Nanoparticle Targeting .....	132
7.8 Future Directions .....	133
Acknowledgements .....	134
References .....	134
 <b>8. Engineering Biocompatible Quantum Dots for Ultrasensitive, Real-Time Biological Imaging and Detection .....</b>	<b>137</b>
<i>Wen Jiang, Anupam Singhal, Hans Fischer, Sawitri Mardiyani, and     Warren C. W. Chan</i>	
8.1 Introduction .....	137
8.2 Synthesis and Surface Chemistry .....	138
8.2.1 Synthesis of QDs that are Soluble in Organic Solvents .....	138
8.2.2 Modification of Surface Chemistry of QDs for Biological Applications .....	141
8.3 Optical Properties .....	142
8.4 Applications .....	146
8.4.1 In Vitro Immunoassays & Nanosensors .....	146
8.4.2 Cell Labeling and Tracking Experiments .....	149
8.4.3 In Vivo Live Animal Imaging .....	150
8.5 Future Work .....	152
Acknowledgements .....	152
References .....	152



<b>9. Diagnostic and Therapeutic Applications of Metal Nanoshells</b> .....	157
<i>Leon R. Hirsch, Rebekah A. Drezek, Naomi J. Halas, and Jennifer L. West</i>	
9.1 Metal Nanoshells .....	157
9.2 Biomedical Applications of Gold Nanoshells .....	161
9.2.1 Nanoshells for Immunoassays .....	161
9.2.2 Photothermally-modulated Drug Delivery Using Nanoshell-Hydrogel Composites .....	162
9.2.3 Photothermal Ablation .....	165
9.2.4 Nanoshells for Molecular Imaging .....	166
References .....	168
<b>10. Nanoporous Microsystems for Islet Cell Replacement</b> .....	171
<i>Tejal A. Desai, Teri West, Michael Cohen, Tony Boiarski, and Arfaan Rampersaud</i>	
10.1 Introduction .....	171
10.1.1 The Science of Miniaturization (MEMS and BioMEMS) .....	171
10.1.2 Cellular Delivery and Encapsulation .....	172
10.1.3 Microfabricated Nanoporous Biocapsule .....	174
10.2 Fabrication of Nanoporous Membranes .....	175
10.3 Biocapsule Assembly and Loading .....	178
10.4 Biocompatibility of Nanoporous Membranes and Biocapsular Environment .....	179
10.5 Microfabricated Biocapsule Membrane Diffusion Studies .....	181
10.5.1 IgG Diffusion .....	183
10.6 Matrix Materials Inside the Biocapsule .....	185
10.6.1 In-Vivo Studies .....	187
10.6.2 Histology .....	188
Conclusion .....	189
Acknowledgements .....	189
References .....	189
<b>11. Medical Nanotechnology and Pulmonary Pathology</b> .....	193
<i>Amy Pope-Harman and Mauro Ferrari</i>	
11.1 Introduction .....	193
11.1.1 Today's Medical Environment .....	194
11.1.2 Challenges for Pulmonary Disease-Directed Nanotechnology Devices .....	195
11.2 Current Applications of Medical Technology in the Lungs .....	196
11.2.1 Molecularly-derived Therapeutics .....	196
11.2.2 Liposomes .....	197
11.2.3 Devices with Nanometer-scale Features .....	198
11.3 Potential uses of Nanotechnology in Pulmonary Diseases .....	198
11.3.1 Diagnostics .....	198
11.3.2 Therapeutics .....	200
11.3.3 Evolving Nanotechnology in Pulmonary Diseases .....	203
11.4 Conclusion .....	207
References .....	208